Carmustine

• 

  Subject Areas on Research

  • A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. 
  • A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. 
  • A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. 
  • A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. 
  • A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects. 
  • Activity of temozolomide in the treatment of central nervous system tumor xenografts. 
  • Acute encephalopathy: a new toxicity associated with high-dose paclitaxel. 
  • Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. 
  • Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience. 
  • An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium. 
  • Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. 
  • Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. 
  • Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. 
  • BCNU as second line therapy for recurrent high-grade glioma previously treated with Temozolomide. 
  • BCNU treatment of marrow stromal monolayers reversibly alters haematopoiesis. 
  • BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial. 
  • BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line. 
  • Bifunctional DNA alkylator 1,3-bis(2-chloroethyl)-1-nitrosourea activates the ATR-Chk1 pathway independently of the mismatch repair pathway. 
  • Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. 
  • Biology of gliomas: potential clinical implications of glioma cellular heterogeneity. 
  • Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. 
  • Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells. 
  • Can O6-alkylguanine-DNA alkyltransferase depletion enhance alkylator activity in the clinic? 
  • Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantation. 
  • Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. 
  • Cisplatin but not BCNU inhibits urokinase-type plasminogen activator levels in human glioblastoma cell lines in vitro. 
  • Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. 
  • Clostridium septicum abscess in hepatic metastases: successful medical management. 
  • Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. 
  • Comparison of intravenous versus intracarotid therapy with 1,3-bis(2-chloroethyl)-1-nitrosourea in a rat brain tumor model. 
  • Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. 
  • Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. 
  • Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. 
  • Correlation of intralesional in vivo chemotherapy of line 10 hepatoma with in vitro drug sensitivity. 
  • Cyclocreatine in cancer chemotherapy. 
  • Cyclophosphamide, cisplatin, and carmustine: pharmacokinetics of carmustine following multiple alkylating-agent interactions. 
  • Cytoprotection by somatostatin of normal and malignant clonogenic cells against the in vitro cytotoxicity of bischloroethylnitrosourea (BCNU). 
  • DNA interstrand crosslinking and strand break repair in human glioma cell lines of varying [1,3-bis(2-chloroethyl)-1-nitrosourea] resistance. 
  • DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. 
  • Decreased DNA interstrand cross-linking and cytotoxicity induced in human brain tumor cells by 1,3-bis(2-chloroethyl)-1-nitrosourea after in vitro reaction with glutathione. 
  • Detecting treatment-by-centre interaction in multi-centre clinical trials. 
  • Effect of cisplatin and BCNU on MMP-2 levels in human glioblastoma cell lines in vitro. 
  • Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. 
  • Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. 
  • Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. 
  • Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. 
  • Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta. 
  • Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. 
  • Evaluating glioma therapies: modeling treatments and predicting outcomes. 
  • Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy. 
  • Evaluation of the lipid-soluble diaminopyrimidines, metoprine and etoprine, in the avian sarcoma virus rat glioma model. 
  • Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. 
  • Formation and repair of 1,3-bis-(2-chloroethyl)-1-nitrosourea and cisplatin induced total genomic DNA interstrand crosslinks in human glioma cells. 
  • Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. 
  • Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. 
  • Glutathione content and glutathione-S-transferase expression in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human malignant astrocytoma cell lines. 
  • Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. 
  • HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. 
  • High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. 
  • High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. 
  • High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. 
  • High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. 
  • High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes. 
  • High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. 
  • High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. 
  • High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. 
  • High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. 
  • High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. 
  • Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. 
  • Immunobiology of primary intracranial tumors. 
  • In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity. 
  • In vitro repair synthesis of BCNU-induced DNA damage. 
  • Independent association of extent of resection with survival in patients with malignant brain astrocytoma. 
  • Interferon-gamma for delayed pulmonary toxicity syndrome resistant to steroids. 
  • Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. 
  • Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea. 
  • Intracellular reduction of selenite into glutathione peroxidase. Evidence for involvement of NADPH and not glutathione as the reductant. 
  • Intracerebral growth of a human glioma tumor line in athymic mice and treatment with procarbazine, 1,3-bis(2-chloroethyl)-1-nitrosourea, aziridinylbenzoquinone, and cis-platinum. 
  • Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it. 
  • Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases. 
  • Mechanisms of resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea in human medulloblastoma and rhabdomyosarcoma. 
  • Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics. 
  • Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). 
  • Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. 
  • Multiple DNA repair mechanisms and alkylator resistance in the human medulloblastoma cell line D-283 Med (4-HCR). 
  • Myocardial ischemia associated with high-dose carmustine infusion. 
  • Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. 
  • O6-benzylguanine-mediated enhancement of chemotherapy. 
  • O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. 
  • Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. 
  • Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy. 
  • Oxidative stress and inflammation contribute to lung toxicity after a common breast cancer chemotherapy regimen. 
  • Permeability of latex and polyvinyl chloride gloves to carmustine. 
  • Pharmacokinetic/pharmacodynamic interactions of intensive cyclophosphamide, cisplatin, and BCNU in patients with breast cancer. 
  • Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. 
  • Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. 
  • Phase I study of BCNU and intravenous 6-mercaptopurine in patients with anaplastic gliomas. 
  • Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. 
  • Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. 
  • Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. 
  • Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms. 
  • Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. 
  • Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. 
  • Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. 
  • Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. 
  • Positive therapeutic interaction between thiopurines and alkylating drugs in human glioma xenografts. 
  • Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. 
  • Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. 
  • Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. 
  • Quenching of DNA cross-link precursors of chloroethylnitrosoureas and attenuation of DNA interstrand cross-linking by glutathione. 
  • Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. 
  • Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. 
  • Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma. 
  • Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. 
  • Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. 
  • Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. 
  • Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. 
  • Stability and compatibility of antitumor agents in glass and plastic containers. 
  • Statin expression in the untreated and SarCNU-exposed human glioma cell line, SK-MG-1. 
  • Stimulation and inhibition of 1,3-bis(2-chloroethyl)-1-nitrosourea-induced strand breaks and interstrand cross-linking in Col E1 plasmid deoxyribonucleic acid by polyamines and inorganic cations. 
  • Synergism between BCNU and irradiation in the treatment of anaplastic gliomas. An in vivo study using the avian sarcoma virus-induced glioma model. 
  • The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. 
  • The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. 
  • The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. 
  • The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. 
  • The role of glutathione reductase in maintaining human granulocyte function and sensitivity to exogenous H2O2. 
  • The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. 
  • Therapy of myeloma. 
  • Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. 
  • Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. 
  • Treatment of autochthonous rat brain tumors with fractionated radiotherapy. The effects of graded radiation doses and of combined therapy with BCNU or steroids. 
  • Treatment of five subcutaneous human glioma tumor lines in athymic mice with carmustine, procarbazine, and mithramycin. 
  • Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. 
  • Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. 
  • White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. 
  • White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy. 
• 

  Keywords of People

  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Yan, Hai, Henry S. Friedman Distinguished Professor of Neuro-Oncology in the School of Medicine, Pathology